Effect of Self-administered Smoke or Smokeless Moxibustion on Breech Presentation Converting to Cephalic Presentatio
- Conditions
- Pregnant women with a singleton breech presentation between 33 and 35 weeks of gestation
- Registration Number
- JPRN-UMIN000021377
- Lead Sponsor
- St. Luke's International University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 60
Not provided
1.Pregnancy with multiples beyond twins, risk of preterm birth (preterm uterine contractions and/or initial dilatation or shortening of the cervix with a score of 4 on the Bishop scale, tocolytic therapy), uterine fibroids > 4cm, maternal heart or kidney disease, placenta previa, complications with pregnancy-induced hypertension, pre-labor rupture of the membranes, contraindication to vaginal delivery, intrauterine growth restriction, fetal malformation or chromosomal disorder, pregnant woman or siblings of the fetus diagnosed with bronchial asthma or a pulmonary problem, and is treated (only in the intervention group) 2.previous uterine surgery, uterine malformations, bone pelvic defects, allergies of Artemisia vulgaris (only in the intervention group), pregnant woman or siblings of the fetus who have symptoms of coughing, respiratory discomfort by smoke (only in the intervention group) 3.prior treatment with moxibustion to achieve version of the fetus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cephalic presentations at two weeks after the start of interventions.
- Secondary Outcome Measures
Name Time Method (1) Cephalic presentations at birth (excluding external cephalic version) (2) Birthing outcomes (the mode of birth, premature birth requiring hospitalization, preterm birth, pre-labor rupture of membranes at < 37 weeks, gestational age at birth, Apgar score < 7 at 5 min., birthweight, admission to NICU, cord blood pH less than 7.1, perinatal morbidity and mortality, (3) The number of self-reported fetal movements. (4) Side effects from using moxa sticks